Melittin: How Bee Venom Disrupts Virus Membranes
Antiviral Peptides
9 virus families inhibited
Melittin, the 26-amino-acid peptide that makes bee stings painful, curbs infectivity across nine different virus families in laboratory studies.
Memariani et al., European Journal of Clinical Microbiology, 2020
Memariani et al., European Journal of Clinical Microbiology, 2020
View as imageThe European honeybee carries a 26-amino-acid weapon in its sting that researchers have been studying for decades: melittin. This single peptide makes up roughly half of bee venom by dry weight, and its ability to punch holes in biological membranes is what makes bee stings hurt. That same membrane-destroying ability is what makes melittin interesting as an antiviral compound. A 2020 review cataloged melittin's activity against nine different virus families, including HIV, herpes simplex, influenza A, and respiratory syncytial virus, with EC50 values in the low microgram-per-milliliter range.[1]
The problem is that melittin destroys everything it touches, viral membranes and human cells alike. The story of melittin as an antiviral is really the story of trying to keep the killing power while losing the toxicity. This article covers what the peptide does, how it does it, what it does to viruses, and where the delivery challenge stands. For context on how plant-derived peptides approach the same problem, see our pillar article on antiviral envelope disruption.
Key Takeaways
- Melittin is a 26-amino-acid amphipathic peptide that constitutes approximately 50% of European honeybee venom by dry weight (Zhang et al., 2024)
- Laboratory studies show antiviral activity against HIV, HSV-1, HSV-2, influenza A, RSV, enterovirus-71, coxsackievirus, vesicular stomatitis virus, and Junin virus (Memariani et al., 2020)
- The lowest effective concentration was against RSV (EC50 = 0.35 ug/mL), which also showed the highest selectivity index of 14.34 (Memariani et al., 2020)
- Melittin disrupts membranes through at least two distinct pathways depending on lipid composition: surface tension modulation in bacterial membranes and direct bilayer penetration in mammalian membranes (Pandidan and Mechler, 2019)
- Engineered melittin derivatives (MDP1) achieved a 252-fold improvement in therapeutic index over native melittin while maintaining rapid bacterial killing (Akbari et al., 2022)
- Virus-like particle delivery systems have demonstrated tumor-specific melittin release in mouse models, pointing toward solutions for the toxicity barrier (Wang et al., 2025)
The Structure That Makes Melittin Lethal
Melittin's sequence is GIGAVLKVLTTGLPALISWIKRKRQQ-NH2. Twenty-six amino acids arranged in a bent rod, or helix-hinge-helix motif. Residues 3 through 10 form one alpha-helix, a proline-containing hinge sits at residues 12 through 14, and residues 15 through 24 form a second, longer alpha-helix.[2]
What makes this structure destructive is its amphipathic organization. The N-terminal half is predominantly hydrophobic. The C-terminal half is polar and cationic, carrying a net positive charge. In solution, melittin exists as a random coil. When it encounters a lipid membrane, it folds into its alpha-helical form, organizing hydrophobic residues on one face and polar residues on the opposite face. This amphipathic helix is the molecular geometry of a membrane destroyer.
Zhang et al. (2024) reviewed the full therapeutic landscape of melittin and its modifications.[2] They noted that melittin's positively charged amino acids enable it to directly punch holes in cell membranes, but this same property causes hemolysis of red blood cells and cytotoxicity that limits clinical applications. The hemolytic activity is not a side effect; it is the same mechanism that gives melittin its antimicrobial and antiviral properties.
How Melittin Destroys Membranes
The mechanism by which melittin disrupts biological membranes is more complex than a simple pore-punch. Pandidan and Mechler (2019) used quartz crystal microbalance fingerprinting to study melittin's interaction with biomimetic membranes and found that the mechanism varies depending on the membrane composition.[3]
In bacterial-mimetic (negatively charged) lipid membranes, viscoelastic fingerprints suggest a surface-acting mechanism where melittin accumulates on the outer leaflet and disrupts membrane integrity through surface tension changes. In mammalian-mimetic (neutral) membranes, melittin appears to penetrate the bilayer at low concentrations, inserting directly into the hydrophobic core.
The classical model held that melittin forms toroidal pores by inserting into the membrane and self-assembling into tetramer structures. Pandidan and Mechler's results were inconsistent with this model and instead proposed two alternative pathways: surface tension modulation leading to toroidal pore formation, or linear aggregation leading to fissure formation.
Wiedman et al. (2013) provided complementary evidence using electrical measurements across lipid bilayers.[4] They found evidence for "transient bilayer permeabilization," where melittin creates temporary openings in the membrane that can reseal. This suggests that membrane disruption is not always a one-way street. At lower concentrations, melittin may create transient permeability events; at higher concentrations, the damage becomes irreversible.
For viruses, the practical outcome is the same regardless of the exact pore mechanism: melittin binding destabilizes the lipid envelope, exposes viral proteins to the extracellular environment, and renders the virus unable to attach to and enter host cells.
Antiviral Activity Across Nine Virus Families
Memariani et al. (2020) compiled the first comprehensive review of melittin's antiviral properties, documenting activity against nine different virus families.[1] The EC50 values reveal substantial variation in sensitivity:
| Virus | EC50 | Selectivity Index |
|---|---|---|
| Respiratory syncytial virus (RSV) | 0.35 ug/mL | 14.34 |
| Enterovirus-71 | 0.76 ug/mL | - |
| Junin virus | 0.86 uM | - |
| HSV-1 | 0.94 ug/mL | - |
| Influenza A (H1N1) | 1.15 ug/mL | - |
RSV showed both the lowest effective concentration and the highest therapeutic window (selectivity index of 14.34), meaning the ratio between the dose that kills the virus and the dose that kills host cells was most favorable.
The antiviral mechanisms go beyond simple envelope disruption. Memariani et al. identified multiple pathways: direct virucidal activity through envelope destruction, impediment of viral multiplication through reduced expression of viral mRNAs, interference with viral attachment and entry, prevention of virus-induced cell fusion, and conformational changes in viral genomes.[1]
For enveloped viruses like HIV, HSV, and influenza, the primary mechanism is direct envelope disruption. Melittin binds to the phospholipid bilayer of the viral envelope through its amphipathic, hydrophobic, and cationic characteristics, then self-assembles into structures that compromise envelope integrity. The virus particle is physically destroyed before it can infect a host cell.
For non-enveloped viruses like enterovirus-71, the mechanism is different and less well understood. Without a lipid envelope to attack, melittin may interact directly with capsid proteins or interfere with viral replication machinery after entry. The evidence for activity against non-enveloped viruses is thinner than for enveloped ones.
The timing of exposure matters. Melittin is most effective when applied directly to virus particles before they contact host cells (pre-treatment), acting as a virucidal agent that physically inactivates viral particles in solution. When added after viral attachment has already occurred, activity drops because the virus has already entered the cell and shed its envelope. This pre-exposure requirement shapes how melittin could be used clinically: as a topical barrier rather than a systemic treatment, applied before exposure rather than after infection is established.
The HIV Nanoparticle Breakthrough
One of the most publicized applications of melittin's antiviral activity came from work at Washington University, where researchers loaded melittin onto perfluorocarbon nanoparticles and tested them against HIV. The nanoparticle construct inhibited both CXCR4-tropic and CCR5-tropic HIV strains in reporter cell assays, with IC50 values of 2.4 uM and 3.6 uM respectively.
The nanoparticle approach solved two problems at once. First, it concentrated melittin at the viral surface where it could attack the HIV envelope. Second, it reduced off-target toxicity: nanoparticle-formulated melittin was fivefold less cytotoxic to sperm and vaginal epithelial cells than free melittin, and was non-toxic at the concentrations needed to inhibit HIV infectivity (10 uM).
This work positioned melittin nanoparticles as a potential topical microbicide for HIV prevention. The concept has not yet advanced to human clinical trials, but it demonstrated that the toxicity problem is solvable with the right delivery platform.
The Toxicity Barrier and How Researchers Are Solving It
Melittin's central limitation is that it kills everything. It destroys viral envelopes, but it also lyses red blood cells, damages epithelial cells, and causes pain and inflammation at injection sites. This is not a side effect that can be optimized away with dose adjustment; it is intrinsic to the mechanism of action.
Akbari et al. (2022) took a different approach: redesigning the peptide itself.[5] They created melittin-derived peptides (MDP1 and MDP2) that maintained rapid bacterial killing kinetics while dramatically reducing toxicity. MDP1 was approximately 100-fold less hemolytic than native melittin and 72.9-fold less cytotoxic to human embryonic kidney cells. The therapeutic index (the ratio between effective dose and toxic dose) improved 252-fold compared to native melittin. MDP1 also showed four to eightfold greater stability in human plasma than the parent peptide.
These improvements came from structural modifications that preserved the amphipathic alpha-helical architecture responsible for membrane activity while reducing the peptide's affinity for mammalian cell membranes. The trade-off between antimicrobial/antiviral potency and host cell toxicity is not fixed; it can be engineered.
Wang et al. (2025) demonstrated a completely different strategy: hiding melittin inside a delivery vehicle that only releases it at the target site.[6] They engineered hepatitis B core virus-like particles (HBc VLPs) to encapsulate melittin, incorporating RGD peptides for tumor targeting and an MMP-2-cleavable linker for tumor-specific release. In mouse melanoma and lung metastasis models, this platform showed effective tumor suppression while protecting healthy tissue from melittin's cytotoxic effects.
While the Wang study targeted cancer rather than viruses, the delivery principle applies directly to antiviral applications. A platform that can release melittin specifically at sites of viral infection while sparing healthy tissue would solve the fundamental barrier to clinical use.
Melittin and Other Antiviral Peptides
Melittin is not the only peptide that kills viruses by attacking their membranes. Lactoferricin, derived from the milk protein lactoferrin, disrupts viral envelopes through a similar amphipathic mechanism. Cyclotides from plants use a different structural scaffold (a cyclic cystine knot) to achieve the same membrane-disrupting effect.
What distinguishes melittin is the combination of potency and simplicity. Its 26-amino-acid sequence is short enough to synthesize cheaply, and its mechanism of action (physical membrane destruction) is difficult for viruses to evolve resistance against. Unlike drugs that target specific viral proteins, membrane-active peptides attack a structural feature that all enveloped viruses share. A virus cannot easily mutate its way out of having a lipid envelope.
This broad-spectrum approach is what makes membrane-disrupting peptides attractive as a class. The challenge for each of them, melittin included, is the same: achieving selective membrane disruption that spares the host.
For a broader overview of bee venom peptides and their therapeutic applications beyond antiviral activity, including antimicrobial and anticancer research, see our dedicated articles.
The Bottom Line
Melittin is a 26-amino-acid amphipathic peptide from bee venom that shows laboratory activity against nine virus families through physical destruction of viral envelopes. EC50 values range from 0.35 ug/mL (RSV) to above 1 ug/mL (influenza A), with RSV showing the best selectivity index of 14.34. The fundamental barrier to clinical use is non-selective cytotoxicity: melittin destroys host cell membranes through the same mechanism it uses on viruses. Engineered derivatives have achieved up to 252-fold improvements in therapeutic index, and nanoparticle delivery systems have demonstrated fivefold reductions in off-target toxicity. No melittin-based antiviral has entered human clinical trials, but the combination of broad-spectrum activity, low resistance potential, and advancing delivery technology keeps it in the research pipeline.